Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure
| Autor: | T. William Jordan, James W. Denham, Peter M. Ferguson, Lisa Woods, David Lamb, Sven Sondhauss, Brett Delahunt, Jonathan C. Dunne, John N. Nacey, Judith Murray |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male Cancer Research Pathology medicine.medical_specialty Biochemical failure Biopsy Blotting Western 03 medical and health sciences Prostate cancer 0302 clinical medicine Antigen Outcome Assessment Health Care Medicine Humans Annexin A2 medicine.diagnostic_test business.industry Prostate Prostatic Neoplasms General Medicine Chemoradiotherapy Prostate-Specific Antigen medicine.disease Prognosis Blot 030104 developmental biology Oncology 030220 oncology & carcinogenesis Localized disease business |
| Zdroj: | Anticancer research. 37(12) |
| ISSN: | 1791-7530 |
| Popis: | BACKGROUND/AIM We previously reported the use of mass spectrometry and western blotting to identify proteins from tumour regions of formalin-fixed paraffin-embedded biopsies from 16 men who presented with apparently localized prostate cancer, and found that annexin A2 (ANXA2) appeared to be a better predictor of subsequent biochemical failure than prostate-specific antigen (PSA). MATERIALS AND METHODS In this follow-up study, ANXA2 and PSA were measured using western blotting of proteins extracted from biopsies from 37 men from a subsequent prostate cancer trial. RESULTS No significant differences in ANXA2 and PSA levels were observed between men with and without biochemical failure. The statistical effect sizes were small, d=0.116 for ANXA2, and 0.266 for PSA. CONCLUSION ANXA2 and PSA proteins measured from biopsy tumour regions are unlikely to be good biomarkers for prediction of the clinical outcome of prostate cancer presenting with apparently localized disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|